Chesley Leslin is the CEO of Boston Lighthouse Innovations (BLI), a company delivering software infrastructure to support high-complexity molecular pathology and NGS-based oncology testing. His career spans helping build and advance clinical genomics capabilities at institutions including Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Weill Cornell Medicine, Beth Israel Deaconess Medical Center, and Oncoclínicas. Across these collaborations, he has focused on translating diagnostic assays into clinical practice with measurable, real-world impact.

At BLI, Chesley leads the development and commercialization of the BioBeam Platform, a cloud-based software suite that transforms raw NGS data into clinical-grade reports.

Chesley also serves as a faculty lead for Northeastern University’s Master of Science in Bioinformatics program in Boston, where he has mentored future leaders in genomic data science since 2009. His work spanning academia and industry continues to drive innovation in scalable cloud-based bioinformatics, clinical decision support, and molecular reporting.